Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Enzalutamide
Drug ID BADD_D00775
Description Enzalutamide is an androgen receptor inhibitor for the treatment of castration-resistant prostate cancer. FDA approved on August 31, 2012.
Indications and Usage Enzalutamide is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.
Marketing Status Prescription
ATC Code L02BB04
DrugBank ID DB08899
KEGG ID D10218
MeSH ID C540278
PubChem ID 15951529
TTD Drug ID D0QK5X
NDC Product Code 54893-0044; 55111-976; 0469-0625; 65392-2209; 68554-0106; 65015-876; 62128-0388; 65129-1376; 59285-018; 42385-733; 0469-0725; 11014-0003; 15308-1121; 0469-0125
Synonyms enzalutamide | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-methyl-benzamide | enzalutamide D3 | HC-1119 | HC 1119 | 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl)-2-fluoro-N-(methyl-d3)benzamide | Xtandi | MDV 3100 | MDV3100 | MDV-3100
Chemical Information
Molecular Formula C21H16F4N4O2S
CAS Registry Number 915087-33-1
SMILES CC1(C(=O)N(C(=S)N1C2=CC(=C(C=C2)C(=O)NC)F)C3=CC(=C(C=C3)C#N)C(F)(F)F)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.0010.091201%
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Ascites09.01.05.003; 07.07.01.001; 02.05.04.002--
Aspartate aminotransferase increased13.03.01.006--
Aspiration22.02.07.0070.001535%
Asthenia08.01.01.0010.225060%Not Available
Atrial fibrillation02.03.03.002--
Atrial flutter02.03.03.0030.002206%
Atrioventricular block complete02.03.01.0030.002206%
B-cell lymphoma16.28.01.001; 01.15.01.0010.001471%Not Available
Back disorder15.03.01.014--Not Available
Back pain15.03.04.0050.120620%
Basal cell carcinoma23.08.02.001; 16.03.02.001--Not Available
Bladder cancer20.03.04.001; 16.08.01.001--Not Available
Bladder neoplasm20.03.04.002; 16.08.03.0020.001471%Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blindness unilateral06.02.02.009; 17.17.01.0160.002942%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood bilirubin increased13.03.01.008--
Blood calcium decreased13.11.01.0020.003677%Not Available
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine abnormal13.13.01.0020.001471%Not Available
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.0010.004413%Not Available
Blood glucose increased13.02.02.002--Not Available
Blood iron decreased13.11.01.0060.001471%Not Available
Blood lactate dehydrogenase increased13.04.02.002--
Blood potassium decreased13.11.01.010--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 23 Pages